FDMT4D Molecular TherapeuticsRunning, no new patients
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Macular Neovascularization Secondary to Age-Related Macular Degeneration
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 480 (planned)
- Started
- Mar 3, 2025
- Main results expected
- Jun 2027
- Fully finished
- Jun 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Mean change from baseline in BCVA ETDRS letter score at Week 52
Measured over: 52 Weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06864988 · record last updated 2026-10-26 · checked 2026-11-09 15:47 UTC